No Data
No Data
Stifel Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $50
Stifel Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $50
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
No Data